KRAS

Biomarkers

KRAS is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
Wild type KRAS	Wild type	7	11
KRAS p.G12C	Somatic Variant	4	5
KRAS p.G12V	Somatic Variant	1	1

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab	FDA
Sensitivity (+)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Panitumumab	FDA
Sensitivity (+)	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib	HC
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab	HC
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan	HC
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan	HC
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab	HC
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab	HC
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan	FDA
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan	FDA
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab	FDA
Sensitivity (+)	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib	FDA
Sensitivity (+)	KRAS p.G12C	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib	FDA
Sensitivity (+)	KRAS p.G12V	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib	FDA
Sensitivity (+)	KRAS p.G12C	Non-Small Cell Lung Cancer	Adagrasib	FDA
Sensitivity (+)	KRAS p.G12C	Colorectal Adenocarcinoma	Adagrasib, Cetuximab	FDA
Sensitivity (+)	HER2-positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Trastuzumab, Tucatinib	FDA